Effects of the COVID-19 pandemic on TB outcomes in the United States: a Bayesian analysis

Background

Preliminary tuberculosis (TB) surveillance data suggest that United States (U.S.) TB cases increased 16% in 2023 compared to 2022 [1]. This rise occurred three years after a 19% reduction in TB cases in 2020 compared to 2019 [2]. These fluctuations represent notable departures from the slow decline in TB cases observed over the prior eight years (2011–2019), during which annual percentage changes ranged from -5.4% to 1.7% [3]. While TB deaths declined by 2% between 2018 and 2019, TB mortality increased sharply following 2019, with the number of persons dying with TB 17% and 21% higher in 2020 and 2021, respectively, compared to 2019 [4]. This variation in TB cases and deaths could have resulted from changes related to the COVID-19 pandemic.

The COVID-19 pandemic disrupted U.S. health services [5, 6], including routine and preventive TB care [7, 8]. Resulting diagnostic delays and treatment interruptions might have increased the duration of infectiousness for TB disease and delayed introduction of life-saving therapy, prolonging morbidity and leading to elevated mortality rates compared to the pre-pandemic period [9, 10]. COVID-19 co-infection might have also led to worse outcomes, including increased mortality, for persons with TB [11, 12].

The COVID-19 pandemic might also have affected TB through changes in immigration. Since 2002 the majority of TB cases in the United States have occurred among non-U.S.–born persons [3]. In 2022, non-U.S–born persons accounted for 72% of total reported TB cases, and 31% of these non-U.S–born cases occurred within four years since entry [3]. As such, TB rates in the United States are sensitive to the number and origin of migrants entering each year [13]. The initial federal response to COVID-19 included provisions that limited immigration into the United States [14]. These efforts led to fewer immigrants between March 2020 and February 2021, followed by a rebound in March 2021 through September 2022 once pandemic measures were relaxed [15]. These immigration changes might also affect long-term TB incidence as 51% of TB cases among non-U.S.–born persons occur in persons who have been in the United States over ten years [3].

Changes in TB transmission during the pandemic might have affected TB epidemiologic trends. Both SARS-CoV-2 and Mycobacterium tuberculosis (Mtb) are spread through respiratory transmission [16]. For this reason, the non-pharmaceutical interventions designed to limit SARS-CoV-2 transmission—such as stay at home orders, physical distancing and face mask use— might have lowered respiratory contact rates, and reduced TB transmission [17, 18].

As these factors were changing simultaneously over the pandemic period, it is difficult to estimate their individual impacts on TB dynamics in the United States based on observational data alone. However, understanding their potential effect on U.S. TB (collectively and individually) is important for predicting future trends and preparing for potential future pandemics. Mathematical models have proven a useful tool for investigating these types of questions, by allowing multiple different evidence sources to be synthesized in an internally consistent framework, constraining estimated outcomes to align with existing epidemiological evidence, and allowing future trends to be forecast under multiple counterfactual scenarios [19, 20].

In this study, we used a transmission dynamic model to investigate the potential impact of COVID-19-associated changes on U.S. TB outcomes. We focused on four potential mechanisms through which COVID-19 might have impacted TB dynamics—changes in immigration, respiratory contact rates, rates of accurate TB diagnosis and treatment initiation (access to care), and mortality rates among persons with TB—and synthesized available data describing these changes over 2020-2023. We estimated the individual and collective impact of these mechanisms on Mtb infections, TB cases, and TB deaths, both during the pandemic period (2020–2023) and over future years (2024–2035), compared to a no-pandemic counterfactual. We used these estimates to describe the potential long-term impacts of COVID-19 pandemic on TB in the United States.

Methods

Results

Fitted pandemic scenario

Figure 1 shows the monthly modeled trend in the mechanism parameters compared with the reported data used to inform the model. Supplementary Figure 1 compares results of the fitted model to reported TB data over the 2020–2023 period.

• Download figure
• Open in new tab

Figure 1:

Comparison of reported trends in COVID-19 adjustment mechanisms to projected trend inputs and modelled trend outputs for each of the four examined mechanisms during 2020–2023.

Note: 1.0 represents equality with pre-pandemic projected levels. As respiratory contact trend is a synthesis of multiple data sources, no reported data is shown for that mechanism. Y-axis is different across parameters.

Future TB outcomes

Figure 2 shows modelled TB outcomes projected to 2035 under the fitted pandemic scenario and no-pandemic counterfactual. During 2020–2035, cumulative cases were estimated to be 132,417 (95% uncertainty interval: 128,670–137,403) under the no-pandemic counterfactual and 135,187 (131,189–140,493) under the fitted pandemic scenario, a difference of 2.1% (1.9–2.3%), or 2,784 (2,164–3,461) additional cases. A majority (74.7% [74.0–75.4%]) of the additional TB cases associated with the pandemic were estimated to occur among non-U.S.–born persons, consistent with pre-pandemic trends.

• Download figure
• Open in new tab

Figure 2:

Model estimated annual TB outcomes under the fitted pandemic scenario and the no-pandemic counterfactual during 2015–2035.*

* Solid lines represent point estimates. Shaded regions represent 95% uncertainty intervals.

Table 1 presents the estimated annual differences in TB outcomes between the fitted pandemic scenario and the no-pandemic counterfactual for selected years. Under the fitted pandemic scenario, annual TB cases were lower over 2020–2022 compared to the counterfactual, resulting in a cumulative 2,500 (2,333–2,682) fewer TB cases during these years. Over 2023–2035, annual TB cases were higher under the fitted pandemic scenario compared to the no-pandemic scenario (5,284 ([4,845–5,794]) additional TB cases).

View this table:

• View inline
• View popup
• Download powerpoint

Table 1:

Net changes in TB outcomes associated with the COVID-19 pandemic in selected calendar years, stratified by nativity. Numbers in parentheses represent 95% uncertainty intervals.

During 2020–2035, 15,428 (15,095–15,844) cumulative TB deaths were estimated under the no-pandemic counterfactual and 16,566 (16,203–17,016) deaths under the fitted pandemic scenario. The estimated 1,138 (1,076–1,201) additional deaths represented a 7.4% (7.2–7.5%) cumulative increase compared with the no-pandemic counterfactual. Under both the fitted pandemic scenario and no-pandemic counterfactual the majority of deaths with TB were among persons who were non-U.S.–born, comprising 80.3% (79.7–80.9%) and 80.5% (80.0–81.2%), respectively. Under the fitted pandemic scenario, estimated annual TB deaths were elevated across the full study period, compared with the no-pandemic counterfactual.

During 2020–2035, an estimated 430,783 (396,390–467,892) incident Mtb infections occurred under the fitted pandemic scenario and 422,752 (389,523–458,475) under the no-pandemic counterfactual, representing a 1.9% (1.6–2.3%) increase.

Impact of individual epidemiological mechanisms

Figure 3A shows the total changes in TB cases and deaths attributable to the changes in each epidemiological mechanism during the pandemic, estimated over the 2020-2035 study period.

• Download figure
• Open in new tab

Figure 3:

Estimated impact of each examined COVID-19 related mechanism on TB outcomes during 2020–2035. A) Cumulative difference in TB outcomes associated with each mechanism B) Annual difference in TB outcomes associated with each mechanism.

Note: Error bars and shaded area represent 95% uncertainty intervals.

Figure 3B depicts time trends in TB cases and deaths associated with each mechanism. For several of these mechanisms we estimated most cumulative mechanism-associated impacts on TB outcomes would occur during 2024–2035, after parameters returned to pre-COVID levels. During 2024–2035, an estimated 3,545 (3,230–3,869) and 2,255 (2,029–2,520) additional TB cases were associated with pandemic-related changes in rates of accurate diagnosis and treatment initiation and immigration, respectively. In contrast, pandemic-related changes in respiratory contact rates were estimated to produce 2,510 (2,260–2,797) fewer TB cases during 2024–2035. Change in TB mortality had its effect on TB cases concentrated during 2020–2023. The impact of pandemic related changes in mechanisms on TB deaths followed similar trends to TB cases.

Supplementary Figure 2 shows the differences in TB outcomes under a sensitivity analysis that varied no-pandemic counterfactual immigration. A 25% reduction in counterfactual (no-pandemic) immigration during 2020–2023 resulted in 3,639 (3,240–4,256) additional TB cases, 344 (305–408) additional TB deaths and 11,503 (10,050 –13,792) under the fitted pandemic scenario over 2020–2035. A 25% increase in counterfactual immigration during 2020–2023 resulted in 4,469 (4,455 –4635) fewer TB cases, 422 (415–434) fewer TB deaths and 13,295 (11,503–15,107) under the fitted pandemic scenario over 2020 –2035.

Discussion

The COVID-19 pandemic caused widespread disruption within the United States during 2020– 2023. In this analysis, we examined pandemic impacts on TB outcomes—as mediated through changes in immigration, respiratory contact rates, access to TB care, and mortality among persons with TB disease—during the 2020-2023 period and modelled long-term effects of the pandemic on TB epidemiology in the United States. During 2020–2035, we estimated 2,770 additional TB cases and 1,138 additional TB deaths due to pandemic-associated changes in TB epidemiology. These overall changes were produced by an initial sharp decrease in TB cases during 2020-2022, followed by an increase in TB cases through 2035. The estimated increase in TB cases might be due, at least in part, to a “catch-up” in the diagnosis of TB cases not diagnosed due to lack of access to TB care or changes in the timing of immigration [1]. Estimated additional deaths due to TB might reflect the elevated frequency of death among those with COVID-19 co-infection and increased disease severity at the time of TB diagnosis, possibly associated with delayed diagnoses [7, 12].

The United States provides a valuable case study of the impact of COVID-19 on TB, in a setting where TB trends are largely driven by reactivation of LTBI among non-U.S.–born persons [3]. Our analysis suggests that the COVID-19 pandemic influenced TB among U.S.-born and non-U.S.–born persons through different mechanisms, demonstrating a mathematical relationship between immigration rates and TB incidence rates among non-U.S.–born persons. The sharp decrease in immigration in 2020 was associated with fewer TB cases among non-U.S.–born persons during 2020–2022. TB cases among non-U.S.–born persons then subsequently increased as TB services returned to pre-pandemic levels and reported immigration rebounded. This positive relationship between migration volume and non-U.S.–born TB rates reflects the disproportionate contribution of recent migrants to U.S. TB case totals, with rates of TB diagnosis for migrants in the years immediately following U.S. entry substantially higher than for U.S.-born persons and long-term residents [30]. In 2023, modeled TB cases totals among non-U.S.–born persons surpassed their modelled no-pandemic counterfactual projection, reflecting increased immigration during 2021–2022 [15].

A number of studies that have investigated the impact of COVID-19 on TB in high incidence settings, but few studies have been published for the United States [7, 10, 12, 31, 32]. An analysis of the 2020–2021 Global Burden of Disease (GBD) estimates reported excess TB deaths among persons under 65 years of age, resulting in an observed to expected deaths ratio of 1.09 (0.983 to 1.20) across all ages [33]. Our model estimates suggest a ratio of 1.20, which falls at the high end of the reported range. This elevated estimate might be due to the exclusion of persons living with HIV in the GBD estimate, a population which has been shown to have increased mortality among persons with TB [12]. Furthermore, we can compare our fitted parameter estimates to empirical metrics. For instance, our estimates of reductions in accurate diagnosis and treatment initiation are consistent with an analysis which found a 37% decrease in sputum smear and culture samples collected during 2020 in two large Californian hospitals [34]. An analysis of emergency department claims among Medicare beneficiaries also found a decrease in TB claims during 2020 [32]. Additionally, the number of reported persons who were identified as contacts of a TB case declined in 2020 [35].

This analysis has several limitations. First, our estimates are sensitive to the assumptions and data used for model fitting, the latter of which were not available for all mechanisms over the total 2020–2023 period. Data used to inform trends in the rates of diagnosis and treatment initiation were only available at a few time points. In contrast, our study benefited from the high quality of U.S. TB surveillance data, which allowed us to calibrate the model to multiple epidemiological metrics and time-points. Secondly, our model did not account for potential changes in TB burden among persons immigrating to the United States. Disruptions in TB care in sender countries might result in increased LTBI incidence among persons who immigrate to the United States [36]. Similarly, the pandemic might have produced shifts in the types of individuals migrating to the United States [37], which could lead to changes in TB rates after U.S. entry. Third, our study chose to explore each mechanism at a national level. However, both TB outcomes and COVID-19 impacts vary substantially across sub-national geographies [38, 39]. Further research examining the sub-national impact of the pandemic on TB outcomes could better inform future public health responses.

This study used mathematical modeling to explore the impact of COVID-19 pandemic on TB in the United States, finding increases in both TB cases and TB deaths during 2020–2035. While the direct impacts of the COVID-19 pandemic occurred between 2020–2023, our analysis suggests these changes might continue to influence TB incidence and mortality in future years.

Author Contributions

N.A.S., N.A.M., and S.M.M. conceived the project. N.A.M. and J.A.S. acquired funding. N.A.S. wrote the model code, drafted the original manuscript, and visualized the results. N.A.S. curated the data and executed the analysis. All authors contributed to the development of the methodology, and reviewed and edited the original manuscript.

Disclaimer

The findings, conclusions, and views expressed are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC).

Funding

This work was supported by the CDC, National Center for HIV, Viral Hepatitis, STD, and TB Prevention Epidemiologic and Economic Modeling Agreement (NEEMA; #5NU38PS004644) (N.A.S., N.A.M., T.C., J.A.S.), and the National Institutes of Health (R01AI146555-02) (C.R.H.).

Data sharing statement

Apart from National TB Surveillance System data, all data used in this analysis represent deidentified publicly available datasets. National TB Surveillance System data contain information abstracted from the national tuberculosis case report form called the Report of Verified Case of Tuberculosis (RVCT) (OMB No. 0920-0728). These data have been reported voluntarily to CDC by state and local health departments and are protected under the Assurance of Confidentiality (Sections 306 and 308(d) of the Public Health Service Act, 42 U.S.C. 242k and 242m(d)), which prevents disclosure of any information that could be used to directly or indirectly identify patients. For more information, see the CDC/ATSDR Policy on Releasing and Sharing Data (at https://stacks.cdc.gov/view/cdc/7563). A limited dataset is available at http://wonder.cdc.gov/tb.html. Researchers seeking additional National TB Surveillance System data may request access through the National Center for Health Statistics’ Research Data Centers (https://www.cdc.gov/rdc/b1datatype/tuberculosis.htm). N.A.S. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.